MicroPort Scientific : ® EP's RhythmWatch™ Single Lead ECG Recorder Gains CF...

Shanghai, China - On November 15, RhythmWatch™ Single lead ECG Recorder, in-house developed by Shanghai MicroPort EP MedTech Co., Ltd. ('MicroPort EP'), obtained the approval from China Food and Drug Administration ('CFDA') (Class II). With the aging population, the prevalence rate of arrhythmia is increasing year by year in China. As the most common type of arrhythmia, atrial fibrillation has high morbidity, long duration, high occurrence rate of complex complications, which may cause myocardial ischemia, cardiac failure, or myocardial infarction, leading to disability or death.

Surface ECG is the most convenient way to diagnose arrhythmia, and electrocardiogram recording of arrhythmia attack is an important basis for the diagnosis of arrhythmia. The time of recording ECG signals by ordinary electrocardiograph is very limited, and it is not easy to capture for paroxysmal arrhythmia. Since the traditional Holter has many limitations, such as patient has to wear it in the hospital, poor comfort, and needed reservation due to a limited number in each hospital, it is not convenient for patients.

RhythmWatch™ Single-lead ECG Recorder is composed of mobile recorders, host software, mobile terminal software and server front-end software. It is designed for medical institutions to collect, record and send ECG signals for patients. RhythmWatch™ Single-lead ECG Recorder is designed in patch style, so patients can wear it for a long time with continuous acquisition of ECG signal. The ECG signals could be replayed with the software. The device could communicate with mobile APP, showing the real-time electrocardiogram, and it can provide immediate view and auxiliary diagnosis for physicians. Through the server front-end software, it can not only make the electrocardiogram display in real time, but also realize the sharing of ECG data. The launch of this device is expected to improve the efficiency of diagnosis and treatment for outpatients, and ease the burden for patients who need follow-up after discharge as well.

RhythmWatch™ Single lead ECG Recorder is the first portable ECG monitoring product of MicroPort EP launched in the China market. Its launch marks another step forward for MicroPort EP in building a complete cardiac EP solution platform. Dr. Yiyong Sun, President of MicroPort EP, said: 'It is well acknowledged that smaller, wireless and smarter electrophysiological medical hardware has a promising future in the era of mobile internet. In the future, MicroPort EP will continue to combine the professional medical service with modern IT technology to develop more innovative products to benefit more patients and doctors.'

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:

Amanda Zhang Corporate Culture & Public Relations Director Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-6989 Email: [e-mail]